In summary, findings of this study demonstrated that the combination of miRNAs including miR-151a-3p or miR-21-5p or miR-126-5p along leptin and miR-151a-3p with glucose can be used as non-invasive biomarker for the comprehensive assessment of steatosis, liver stiffness and hepatic fat content, which are critical factors in determining the presence of MASLD. Here, LEP is linked to steatosis.